Involved-field radiotherapy for advanced Hodgkin's lymphoma - PubMed (original) (raw)
Clinical Trial
. 2003 Jun 12;348(24):2396-406.
doi: 10.1056/NEJMoa022628.
John M M Raemaekers, Umberto Tirelli, Roberto Bortolus, Mars B van 't Veer, Marnix L M Lybeert, Jo J Keuning, Patrice Carde, Théodore Girinsky, Richard W M van der Maazen, Radka Tomsic, Marjeta Vovk, Achilles van Hoof, Geertrui Demeestere, Pieternella J Lugtenburg, José Thomas, Wilfried Schroyens, Koenraad De Boeck, Johanna W Baars, Johanna C Kluin-Nelemans, Christian Carrie, Malek Aoudjhane, Dominique Bron, Houchingue Eghbali, Wilma G J M Smit, Jacobus H Meerwaldt, Anton Hagenbeek, Antonella Pinna, Michel Henry-Amar; European Organization for Research and Treatment of Cancer Lymphoma Group
Affiliations
- PMID: 12802025
- DOI: 10.1056/NEJMoa022628
Free article
Clinical Trial
Involved-field radiotherapy for advanced Hodgkin's lymphoma
Berthe M P Aleman et al. N Engl J Med. 2003.
Free article
Abstract
Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial.
Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites.
Results: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively.
Conclusions: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy.
Copyright 2003 Massachusetts Medical Society
Comment in
- Hodgkin's disease--clinical trials and travails.
DeVita VT Jr. DeVita VT Jr. N Engl J Med. 2003 Jun 12;348(24):2375-6. doi: 10.1056/NEJMp030049. N Engl J Med. 2003. PMID: 12802021 No abstract available. - Radiotherapy for advanced Hodgkin's disease.
Gupta T, Sanghavi V, Laskar S. Gupta T, et al. N Engl J Med. 2003 Sep 18;349(12):1187-8; author reply 1187-8. doi: 10.1056/NEJM200309183491218. N Engl J Med. 2003. PMID: 13679537 No abstract available.
Similar articles
- Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
Aleman BM, Raemaekers JM, Tomiŝiĉ R, Baaijens MH, Bortolus R, Lybeert ML, van der Maazen RW, Girinsky T, Demeestere G, Lugtenburg P, Lievens Y, de Jong D, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group. Aleman BM, et al. Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):19-30. doi: 10.1016/j.ijrobp.2006.08.041. Epub 2006 Nov 9. Int J Radiat Oncol Biol Phys. 2007. PMID: 17097834 Clinical Trial. - Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Fermé C, et al. N Engl J Med. 2007 Nov 8;357(19):1916-27. doi: 10.1056/NEJMoa064601. N Engl J Med. 2007. PMID: 17989384 Clinical Trial. - Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M. Noordijk EM, et al. J Clin Oncol. 2006 Jul 1;24(19):3128-35. doi: 10.1200/JCO.2005.05.2746. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754934 Clinical Trial. - [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R, Gil-Fernández JJ, Muñoz E, Acevedo A, Sobrino MP, Fernández-Rañada JM. Arranz R, et al. Sangre (Barc). 1998 Jun;43(3):179-84. Sangre (Barc). 1998. PMID: 9741222 Review. Spanish. - The case against the routine use of radiation therapy in advanced-stage Hodgkin's disease.
Longo DL. Longo DL. Cancer Invest. 1996;14(4):353-60. doi: 10.3109/07357909609012163. Cancer Invest. 1996. PMID: 8689431 Review. No abstract available.
Cited by
- Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials.
Juul SJ, Rossetti S, Aleman BMP, van Leeuwen FE, van der Kaaij MAE, Giusti F, Meijnders P, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Krzisch D, Bigenwald C, Stamatoullas A, André M, Plattel WJ, Hutchings M, Maraldo MV. Juul SJ, et al. J Cancer Surviv. 2024 Oct 18. doi: 10.1007/s11764-024-01694-0. Online ahead of print. J Cancer Surviv. 2024. PMID: 39422824 - Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study.
Chugh S, Panda G, Mokal S, Jain H, Bagal B, Khanna N, Epari S, Punatar S, Nayak L, Gokarn A, Khattry N, Sengar M, Laskar S, Goda JS. Chugh S, et al. Indian J Med Res. 2024 Feb 1;159(2):193-205. doi: 10.4103/ijmr.ijmr_3459_21. Epub 2024 Apr 4. Indian J Med Res. 2024. PMID: 38577858 Free PMC article. - Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials.
Hughes RT, Razavian NB, Shenker RF, Kelsey CR, Smith S, D'Agostino RB Jr, Winkfield KM. Hughes RT, et al. Adv Radiat Oncol. 2024 Jan 30;9(5):101450. doi: 10.1016/j.adro.2024.101450. eCollection 2024 May. Adv Radiat Oncol. 2024. PMID: 38550369 Free PMC article. - Consolidative mediastinal radiotherapy for advanced-stage classical Hodgkin lymphoma with bulky disease in patients who achieve complete response after chemotherapy in PET-CT era.
Atanazio MJ, Santos FM, Duran A, Maia ACA, Alves LB, Velasques RD, Rocha V, Buccheri V. Atanazio MJ, et al. Rep Pract Oncol Radiother. 2022 Oct 31;27(5):856-862. doi: 10.5603/RPOR.a2022.0092. eCollection 2022. Rep Pract Oncol Radiother. 2022. PMID: 36523799 Free PMC article. - Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials.
Juul SJ, Rossetti S, Kicinski M, van der Kaaij MAE, Giusti F, Meijnders P, Aleman BMP, Raemaekers JMM, Kluin-Nelemans HC, Spina M, Fermé C, Renaud L, Casasnovas O, Stamatoullas A, André M, Le Bras F, Plattel WJ, Henry-Amar M, Hutchings M, Maraldo MV. Juul SJ, et al. J Cancer Surviv. 2024 Jun;18(3):727-738. doi: 10.1007/s11764-022-01305-w. Epub 2022 Nov 28. J Cancer Surviv. 2024. PMID: 36441393
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical